CEVR analyzes the value of strategies to improve health and health care.

About Us

News

New CEVR Study Examines Coverage Policies for Cell and Gene Therapies

Boston, MA, September 30, 2025 — A new study from the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center provides ne...

Read more September 30, 2025

David Strutton, PhD, to Join Tufts-CEVR as Senior Fellow

Boston, MA – July 29, 2025 – The Center for the Evaluation of Value and Risk in Health (CEVR), part of the Institute for Clinical Research and Health ...

Read more July 29, 2025

In remembrance of John Iglehart

In remembrance of John Iglehart By Peter J. Neumann The passing of John Iglehart, the Founding Editor of Health Affairs, and a monumental figure in t...

Read more June 23, 2025

View All News Items

Events

CEVR Health Policy Seminar with Carl Asche, PhD, MSc

2:00–3:00 on September 30, 2025

CEVR Health Policy Seminar with Nathaniel Hendrix, PhD, PharmD

2:00–3:00 on June 17, 2025

CEVR Health Policy Seminar with Noemi Kreif, PhD

4:00–5:00 on May 6, 2025

View All Events

Recent Publications

Vaccine

Family spillover effects in cost-effectiveness analyses of vaccines

View publication

September 19, 2025

Alzheimers & Dementia

Characterizing financial risk from out-of-pocket expenditures across dementia stages

View publication

September 15, 2025

Health Affairs

Health Technology Assessment, Again: A Transparent, Evidence-Based Approach For CMS Drug Price Negotiations

View publication

August 4, 2025

Journal of Comparative Effectiveness Research

Value assessment for health services and procedures: a call to action in a new political climate

View publication

July 18, 2025

Health Affairs Scholar

What drug characteristics explain the wide range of manufacturer rebates?

View publication

July 15, 2025

Value in Health

Achieving Patient-Centered Value/Health Technology Assessment: Recommendations From a Multistakeholder eDelphi Panel

View publication

July 7, 2025

Health Affairs

Drug coverage policies and clinical guidelines alignment: Most coverage decisions include additional restrictions

View publication

July 7, 2025

Frontiers in Pharmacology

Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability

View publication

July 2, 2025

View All Publications

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.

CEA Registry

The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.

Global Health CEA Registry

The GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.

SPEC Database

The Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.

Learn About Our Databases